MAY 22, 2018 9:04 PM PDT

An Antibody Proven Effective in Treating Severe Asthma

WRITTEN BY: Nouran Amin

Severe asthma is a subtype of asthma where treatments usually do not have any effect on the individual.

 

 

Present treatments for severe asthma more than often involve increased doses of corticosteroids, such as prednisone, in order to control exacerbations. Decreasing the dependence for corticosteroids with alternative options is desirable, since these medicines are often associated with serious side effects from long-term use, such as multi-organ toxicities and immunosuppression.

Now, investigators at McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton, in collaboration with other partnering institutions, have found a new method in treating severe asthma. Through a study of over 200 participants with severe asthma, the developed treatment was seen to improve symptoms of asthma and lung function, while decreasing the need for corticosteroids for up to 70%.

Professor of medicine and pulmonologist, Dr. Parameswaran Nair, at St. Joseph's Healthcare Hamilton in McMaster University, plus a team of investigators have isolated an antibody by the name dupilumab which holds high efficacy in the treatment of severe asthma in comparison to high doses of prednisone. More so, the researchers sought participants who were using oral corticosteroids (prednisone) for at least 6 months to treat their severe asthma. For a 24 week period, these participants used dupilumab in addition to their standard regimen of corticosteroids, however, the corticosteroid doses was gradually lowered over the 24 weeks. "The ability of dupilumab to increase lung function as markedly as it did in this study, even in the face of [corticosteroid] withdrawal, indicates that it appears to be inhibiting key drivers of lung inflammation," the researchers noted.

Dupilumab is essentially an inhibitor that works to treat asthma by blocking two specific protein known as interleukin-4 and interleukin-13 which are associated with inflammation of the airways. Studies on Dupilumab were based on previous published work by Dr. Nair. Those studies found that inhibiting the function of another protein, interleukin-5, allowed patients with high eosinophil levels in their blood and airways to lower their corticosteroid dose. Eosinophils are a subtype of white blood cells that are involved with the production of interleukins. Increased eosinophil levels are directly linked to a high risk of severe asthma.

In comparison to the previous studies, dupilumab was shown to be effective regardless of the affected individuals eosinophil levels. Even though the prednisone levels were reduced, patients in this study not only experienced a decrease in asthma exacerbations, but their lung function also improved. "Ultimately, our goal is to find new treatment pathways that allow us to circumvent the use of corticosteroids," said Dr. Nair. "Since dupilumab showed a significant improvement on asthma control regardless of eosinophil levels, we may be able to use this treatment for a wider range of patients than we previously thought possible. This might be due to the broad effects on inflammation in asthma of the two proteins that we were able to block with dupilumab. The treatment was not associated with any serious side effects."

 

Sources: New England Journal of Medicine

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 20, 2022
Microbiology
Rapid AST: A key weapon in the fight against AMR
APR 20, 2022
Rapid AST: A key weapon in the fight against AMR
Despite the dire, well-documented risks of antimicrobial resistance (AMR), which threatens to kill 10 million people a y ...
APR 19, 2022
Health & Medicine
Pandemic Creates Opportunity to Study Rare Vaccine Side Effects
APR 19, 2022
Pandemic Creates Opportunity to Study Rare Vaccine Side Effects
The Global Vaccine Data Network (GVDN) is a project conceived over 10 years ago to study vaccine side effects. Back then ...
APR 28, 2022
Drug Discovery & Development
Essential Vitamins and Minerals Help Children with ADHD and Emotional Dysregulation
APR 28, 2022
Essential Vitamins and Minerals Help Children with ADHD and Emotional Dysregulation
Conditions like attention deficit hyperactivity disorder (ADHD) have become increasingly common. An estimated 6.1 millio ...
MAY 07, 2022
Drug Discovery & Development
Ibuprofen and Blood Pressure Medication Linked to Kidney Damage
MAY 07, 2022
Ibuprofen and Blood Pressure Medication Linked to Kidney Damage
A combination of ibuprofen and certain blood pressure medications could lead to acute kidney injury. The corresponding s ...
MAY 12, 2022
Cannabis Sciences
Cannabis Use Impacts Sleep Duration
MAY 12, 2022
Cannabis Use Impacts Sleep Duration
Frequency of cannabis use may be the reason some people get too little or too much sleep. A recent study published in th ...
MAY 13, 2022
Drug Discovery & Development
Opioid Addiction Treatments Minimize Fetal Brain Changes
MAY 13, 2022
Opioid Addiction Treatments Minimize Fetal Brain Changes
The rise in opioid use, addiction, and overdose is a serious public health matter. Almost 850,000 people have died of dr ...
Loading Comments...